NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET

Company Participants

Suzanne Messere - IR

Stephen Willard - CEO

Seth Van Voorhees - CFO

Jonathan Javitt - Chief Scientist

Conference Call Participants

Jason Kolbert - Dawson James

Vernon Bernadino - H.C. Wainwright

Ed Woo - Ascendiant Capital

Operator

Good afternoon and welcome to the NRx Pharmaceuticals Full Year 2022 Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Suzanne Messere, Stern Investor Relations. Please go ahead.

Suzanne Messere

Thank you, Danielle. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under US Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as the date hereof and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued earlier today and in the company's Form 10-K planned to be filed tomorrow, which may be accessed from the Investor Relations sections of the NRx Pharmaceuticals' website.

Joining me on today's call from NRx Pharmaceuticals are Stephen Willard, Chief Executive Officer and Seth Van Voorhees, Chief Financial Officer and Treasurer.

Stephen will provide a summary of the company's progress; Seth will review the company's financial results, and then Stephen will review upcoming milestones before making closing comments.

Following their prepared remarks, Stephen and Seth will be joined by Jonathan Javitt, the company's Chief Scientist and Matthew Duffy, the company's Chief Business Officer to address your questions.

I will now turn the call over to Stephen.

Stephen Willard

Thank you, Suzanne. Good afternoon everyone and thank you for joining us. We scheduled this conference call to coincide with World Bipolar Day. As you know, bipolar depression is a lethal condition that affects 2% of Americans, nearly 7 million people and a similar percentage of the world's population. With the commitment of our investors, our team, and our researchers, we aim to literally bring hope to the millions of patients with suicidal bipolar depression and PTSD who have been systematically excluded from the trials of previous antidepressants.